Patents by Inventor Mark Guido

Mark Guido has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-CD30 monoclonal antibodies and chimeric antigen receptors
    Publication number: 20240124598
    Abstract: Antibodies, fragments thereof, and chimeric proteins comprising same are presented that have specific binding activity against CD30. Advantageously, contemplated molecules can be used in pharmaceutical compositions for immune therapy, particularly in individuals diagnosed with hematopoietic malignancies, including Hodgkin lymphoma, CD30-positive B cell lymphomas, CD30-positive T cell lymphomas, CD30-positive NK cell lymphomas.
    Type: Application
    Filed: September 8, 2023
    Publication date: April 18, 2024
    Applicant: NantBio, Inc.
    Inventors: Clifford Anders Olson, Kayvan Niazi, Helty Adisetiyo, Hermes J. Garban, Mark Guido, Heather McFarlane, Tan Trinh, Shiho Tanaka
  • Anti-CD30 monoclonal antibodies and chimeric antigen receptors
    Patent number: 11814436
    Abstract: Antibodies, fragments thereof, and chimeric proteins comprising same are presented that have specific binding activity against CD30. Advantageously, contemplated molecules can be used in pharmaceutical compositions for immune therapy, particularly in individuals diagnosed with hematopoietic malignancies, including Hodgkin lymphoma, CD30-positive B cell lymphomas, CD30-positive T cell lymphomas, CD30-positive NK cell lymphomas.
    Type: Grant
    Filed: February 24, 2022
    Date of Patent: November 14, 2023
    Assignee: NantBio, Inc.
    Inventors: Clifford Anders Olson, Kayvan Niazi, Helty Adisetiyo, Hermes J. Garban, Mark Guido, Heather McFarlane, Tan Trinh, Shiho Tanaka
  • Anti-CD30 monoclonal antibodies and chimeric antigen receptors
    Publication number: 20220275098
    Abstract: Antibodies, fragments thereof, and chimeric proteins comprising same are presented that have specific binding activity against CD30. Advantageously, contemplated molecules can be used in pharmaceutical compositions for immune therapy, particularly in individuals diagnosed with hematopoietic malignancies, including Hodgkin lymphoma, CD30-positive B cell lymphomas, CD30-positive T cell lymphomas, CD30-positive NK cell lymphomas.
    Type: Application
    Filed: February 24, 2022
    Publication date: September 1, 2022
    Applicant: NantBio, Inc.
    Inventors: Clifford Anders Olson, Kayvan Niazi, Helty Adisetiyo, Hermes J. Garban, Mark Guido, Heather McFarlane, Tan Trinh, Shiho Tanaka